Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.

ABSTRACT:

Background

Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have identified important candidates for targeted therapy, most have relied on few NEPC patients due to disease rarity, resulting in thousands of differentially expressed genes collectively and offering an opportunity for meta-analysis. Moreover, past studies have focused on prototypical NEPC samples with classic immunohistochemistry profiles, whereas there is increasing recognition of atypical phenotypes. In the primary setting, small cell prostatic carcinoma (SCPC) is frequently admixed with ade

SUBMITTER: Tsai HK 

PROVIDER: S-EPMC5683385 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature